OncoCyte Corp Financials
| OCX Stock | USD 2.71 0.04 1.50% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.84 | 1.4871 |
|
|
The essential information of the day-to-day investment outlook for OncoCyte Corp includes many different criteria found on its balance sheet. An individual investor should monitor OncoCyte Corp's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in OncoCyte Corp.
Net Income |
|
OncoCyte | Select Account or Indicator |
Understanding current and past OncoCyte Corp Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of OncoCyte Corp's financial statements are interrelated, with each one affecting the others. For example, an increase in OncoCyte Corp's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in OncoCyte Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of OncoCyte Corp. Check OncoCyte Corp's Beneish M Score to see the likelihood of OncoCyte Corp's management manipulating its earnings.
OncoCyte Corp Stock Summary
OncoCyte Corp competes with Burning Rock, Neuronetics, DarioHealth Corp, Sera Prognostics, and Fonar. OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Oncocyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US68235C1071 |
| CUSIP | 68235C107 68235C206 |
| Location | California; U.S.A |
| Business Address | 15 Cushing, Irvine, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.oncocyte.com |
| Phone | 949 409 7600 |
| Currency | USD - US Dollar |
OncoCyte Corp Key Financial Ratios
| Return On Equity | -1.65 | ||||
| Operating Margin | (55.43) % | ||||
| Price To Sales | 64.35 X | ||||
| Revenue | 1.5 M | ||||
| Gross Profit | 188 K |
OncoCyte Corp Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 39.9M | 55.4M | 159.6M | 100.1M | 74.9M | 49.1M | |
| Other Current Liab | 2.6M | 5.3M | 9.4M | 9.2M | 4.9M | 4.7M | |
| Net Debt | (16.1M) | 1.5M | (29.9M) | (16.4M) | (6.6M) | (6.9M) | |
| Retained Earnings | (93.7M) | (123.7M) | (187.8M) | (260.7M) | (289.9M) | (275.4M) | |
| Accounts Payable | 469K | 432K | 1.8M | 1.3M | 953K | 621.2K | |
| Cash | 22.1M | 7.1M | 35.6M | 20.0M | 9.4M | 12.8M | |
| Other Assets | 2.2M | 2.1M | 2.0M | 1.0 | 1.15 | 1.09 | |
| Other Current Assets | 505K | 1.2M | 3.9M | 3.1M | 782K | 1.1M | |
| Total Liab | 9.0M | 21.9M | 94.3M | 65.8M | 49.3M | 27.1M | |
| Total Current Assets | 23.0M | 9.2M | 39.1M | 25.5M | 10.7M | 15.7M | |
| Short Term Debt | 1.4M | 3.2M | 3.0M | 1.6M | 1.3M | 1.7M | |
| Common Stock | 124.6M | 157.2M | 253.0M | 294.9M | 310.3M | 325.8M | |
| Net Tangible Assets | 30.8M | 9.3M | (44.7M) | (22.0M) | (19.8M) | (18.8M) | |
| Long Term Debt | 1.1M | 347K | 1.9M | 1.5M | 1.7M | 905.1K | |
| Long Term Debt Total | 1.4M | 534K | 2.0M | 1.5M | 1.7M | 1.2M | |
| Net Invested Capital | 33.9M | 37.4M | 66.5M | 34.3M | 20.5M | 32.0M | |
| Net Working Capital | 18.5M | 230K | 25.0M | 13.4M | 3.5M | 3.3M | |
| Capital Stock | 124.6M | 157.2M | 253.0M | 294.9M | 310.3M | 222.7M |
OncoCyte Corp Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 299K | 252K | 209K | 77K | 52K | 49.4K | |
| Operating Income | (22.2M) | (29.7M) | (46.9M) | (18.0M) | (25.1M) | (26.4M) | |
| Ebit | (22.0M) | (30.9M) | (52.7M) | (18.5M) | (24.8M) | (26.0M) | |
| Research Development | 6.8M | 9.8M | 13.6M | 7.3M | 9.3M | 7.8M | |
| Ebitda | (21.7M) | (30.5M) | (48.5M) | (13.3M) | (23.1M) | (24.3M) | |
| Income Before Tax | (22.4M) | (31.2M) | (73.4M) | (18.6M) | (24.9M) | (26.1M) | |
| Net Income | (22.3M) | (29.9M) | (64.1M) | (73.4M) | (27.8M) | (29.2M) | |
| Total Revenue | 16K | 1.2M | 7.7M | 958K | 1.5M | 1.3M | |
| Gross Profit | (344K) | (639K) | 188K | (18K) | 413K | 433.7K | |
| Cost Of Revenue | 344K | 1.9M | 7.5M | 976K | 1.1M | 1.5M | |
| Income Tax Expense | (97K) | (1.3M) | (9.3M) | 54.8M | 2.9M | 5.1M | |
| Net Interest Income | 299K | (252K) | (209K) | (77K) | 96K | 100.8K |
OncoCyte Corp Key Cash Accounts
Cash flow analysis captures how much money flows into and out of OncoCyte Corp. It measures of how well OncoCyte is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money OncoCyte Corp brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money OncoCyte had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what OncoCyte Corp has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 15.7M | (14.9M) | 28.5M | (14.1M) | (12.1M) | (11.5M) | |
| Free Cash Flow | (20.6M) | (27.2M) | (38.2M) | (49.9M) | (23.6M) | (24.8M) | |
| Depreciation | 351K | 1.9M | 4.2M | 5.2M | 1.7M | 1.6M | |
| Other Non Cash Items | 437K | (2.2M) | 28.6M | 14.0M | 174K | 165.3K | |
| Capital Expenditures | 918K | 1.2M | 2.2M | 4.3M | 281K | 267.0K | |
| Net Income | (22.4M) | (29.9M) | (64.1M) | (72.9M) | (27.8M) | (29.2M) | |
| End Period Cash Flow | 23.8M | 8.8M | 37.3M | 23.2M | 11.1M | 13.8M | |
| Investments | (11.2M) | (4M) | (14.0M) | (4.3M) | (932K) | (978.6K) | |
| Net Borrowings | 2.3M | 695K | (1.5M) | (1.3M) | (1.2M) | (1.1M) | |
| Change To Netincome | 3.8M | 1.5M | 23.7M | 24.0M | 27.7M | 29.0M |
OncoCyte Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining OncoCyte Corp's current stock value. Our valuation model uses many indicators to compare OncoCyte Corp value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across OncoCyte Corp competition to find correlations between indicators driving OncoCyte Corp's intrinsic value. More Info.OncoCyte Corp is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, OncoCyte Corp's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the OncoCyte Corp's earnings, one of the primary drivers of an investment's value.OncoCyte Corp Systematic Risk
OncoCyte Corp's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. OncoCyte Corp volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on OncoCyte Corp correlated with the market. If Beta is less than 0 OncoCyte Corp generally moves in the opposite direction as compared to the market. If OncoCyte Corp Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one OncoCyte Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of OncoCyte Corp is generally in the same direction as the market. If Beta > 1 OncoCyte Corp moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in OncoCyte Corp Stock are looking for potential investment opportunities by analyzing not only static indicators but also various OncoCyte Corp's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of OncoCyte Corp growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
OncoCyte Corp November 24, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of OncoCyte Corp help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of OncoCyte Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of OncoCyte Corp based on widely used predictive technical indicators. In general, we focus on analyzing OncoCyte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build OncoCyte Corp's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 18.12 | |||
| Value At Risk | (4.76) | |||
| Potential Upside | 4.59 |
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.